United Therapeutics Corporation Share Price & Technical Analysis
UTHR · $568.4 (+0.45%)
Healthcare / Drug Manufacturers - Specialty & Generic
$568.4
+0.45%
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) …
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
0% return in May, 3% avg return in past 3 year May month.
16% return in 2026, 11% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -4% | 8% | 16% | -4% | 0% | – | – | – | – | – | – | – | 16% |
| 25 | 0% | -8% | -3% | -2% | 5% | -10% | -4% | 7% | 0% | 6% | 10% | 1% | 1% |
| 24 | -2% | 5% | 1% | 3% | 13% | 16% | -1% | 16% | -1% | 4% | -1% | -6% | 47% |
| 23 | -5% | -6% | -9% | 3% | -9% | 5% | 10% | -8% | 0% | -1% | 13% | -9% | -13% |
| 22 | -6% | -18% | 8% | -2% | 30% | 1% | -1% | -2% | -7% | 9% | 22% | -1% | 34% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Uptrend · Neutral
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$24.52B
P/E ratio
21.35
52W high
$609.4
52W low
$272.1
Volume
2,81,044
Beta
0.59
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is United Therapeutics Corporation share price today?
- United Therapeutics Corporation (UTHR) last traded around $568.4 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does UTHR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for UTHR. Download the app for real-time alerts.
- How can I analyze United Therapeutics Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.